Omeros drops 37% as lead product misses knee surgery postop function endpoints
This article was originally published in Scrip
Executive Summary
Omeros saw its stock plummet 37% after it revealed that OMS103HP, its proprietary combination of ketoprofeon, amitriptyline and oxymetazoline, to improve knee function and reduce postoperative pain following arthroscopic anterior cruciate ligament (ACL) reconstruction surgery, failed to meet pre-specified endpoints in Phase III trials. Omeros shares fell $2.94, or 37%, to $5.06 in late trading on 1 April.